Elan Pharmaceuticals, LLC v. Sexton

CourtDistrict Court, D. Kansas
DecidedOctober 1, 2019
Docket2:19-cv-02175
StatusUnknown

This text of Elan Pharmaceuticals, LLC v. Sexton (Elan Pharmaceuticals, LLC v. Sexton) is published on Counsel Stack Legal Research, covering District Court, D. Kansas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Elan Pharmaceuticals, LLC v. Sexton, (D. Kan. 2019).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF KANSAS

ELAN PHARMACEUTICALS, LLC, ELI LILLY & COMPANY, and AVID RADIOPHARMACEUTICALS, INC.,

Plaintiffs, Case No. 2:19-CV-02175-JAR-GEB

v.

RONALD SEXTON,

Defendant.

MEMORANDUM AND ORDER Plaintiffs Elan Pharmaceuticals, LLC (“Elan”), Eli Lilly & Company (“Eli Lilly”), and Avid Radiopharmaceuticals, Inc. (“Avid”) bring this action against Defendant Ronald Sexton (“Sexton”) for an award of attorneys’ fees pursuant to 35 U.S.C. § 285 (Count I) and for malicious prosecution (Count II). Now before the Court is Defendant’s Motion to Dismiss (Doc. 14) pursuant to Federal Rule of Civil Procedure 12(b)(6). The motion is fully briefed, and the Court is prepared to rule. For the reasons explained below, the Court grants Defendant’s motion. I. Legal Standard

To survive a motion to dismiss brought under Fed. R. Civ. P. 12(b)(6), a complaint must contain factual allegations that, assumed to be true, “raise a right to relief above the speculative level”1 and must include “enough facts to state a claim for relief that is plausible on its face.”2 Under this standard, “the complaint must give the court reason to believe that this plaintiff has a

1Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007) (citing 5C Charles Alan Wright & Arthur R. Miller, Federal Practice and Procedure § 1216, at 235–36 (3d ed. 2004)). 2Id. at 570. reasonable likelihood of mustering factual support for these claims.”3 The plausibility standard does not require a showing of probability that “a defendant has acted unlawfully,” but requires more than “a sheer possibility.”4 “[M]ere ‘labels and conclusions,’ and ‘a formulaic recitation of the elements of a cause of action’ will not suffice; a plaintiff must offer specific factual allegations to support each claim.”5 Finally, the court must accept the nonmoving party’s factual

allegations as true and may not dismiss on the ground that it appears unlikely the allegations can be proven.6 The Supreme Court has explained the analysis as a two-step process. For the purposes of a motion to dismiss, the court “must take all the factual allegations in the complaint as true, [but is] ‘not bound to accept as true a legal conclusion couched as a factual allegation.’”7 Thus, the court must first determine if the allegations are factual and entitled to an assumption of truth, or merely legal conclusions that are not entitled to an assumption of truth.8 Second, the court must determine whether the factual allegations, when assumed true, “plausibly give rise to an entitlement to relief.”9 “A claim has facial plausibility when the plaintiff pleads factual content

that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.”10

3Ridge at Red Hawk, L.L.C. v. Schneider, 493 F.3d 1174, 1177 (10th Cir. 2007). 4Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citing Twombly, 550 U.S. at 556). 5Kan. Penn Gaming, LLC v. Collins, 656 F.3d 1210, 1214 (10th Cir. 2011) (quoting Twombly, 550 U.S. at 555). 6Iqbal, 556 U.S. at 678 (citing Twombly, 550 U.S. at 555). 7Id. (quoting Twombly, 550 U.S. at 555). 8Id. at 678–679. 9Id. at 679. 10Id. at 678 (citing Twombly, 550 U.S. at 556). II. Factual Background

The following facts are alleged in Plaintiffs’ Complaint and are assumed to be true for the purposes of deciding Sexton’s motion to dismiss.11 Defendant Sexton, a resident of Johnson County, Kansas, is the Chairman and founder of AIA America, Inc., formerly known as Alzheimer’s Institute of America, Inc. (“AIA”). Sexton founded AIA as a shell, instrumentality, or conduit to prosecute patent lawsuits. Sexton dominated and controlled AIA, commingled AIA’s funds with his personal funds, failed to adequately capitalize AIA, and failed to maintain adequate corporate records and observe corporate formalities. AIA paid no dividends, and no one other than Sexton functioned as an officer or director of AIA. On February 2, 2010, AIA filed a lawsuit against Elan and Eli Lilly in the United States District Court for the Northern District of California (“Elan Court”), asserting claims for alleged infringement of two AIA patents (“Elan Lawsuit”). On November 24, 2010, AIA filed a lawsuit against Avid in the United States District Court for the Eastern District of Pennsylvania (“Avid

Court”), asserting essentially the same patent-infringement claims (“Avid Lawsuit”). The two patents at issue in both cases were “generally directed to research technologies stemming from the discovery of the ‘Swedish mutation,’ a genetic mutation that is associated with early-onset familia[l] Alzheimer’s disease.”12 In the Avid Lawsuit, Avid asserted that AIA lacked standing to assert the patents on the basis that Sexton and others—namely, Dr. Michael J. Mullan and Dr. John Hardy—had

11Although Sexton attaches outside materials to his motion to dismiss, the Court need not consider those materials in ruling on Sexton’s motion and, therefore, does not consider whether to convert Sexton’s motion to one for summary judgment under Fed. R. Civ. P. 56. 12Doc. 1 ¶ 12 (quoting AIA Am., Inc., v. Avid Radiopharmaceuticals, Inc., 866 F.3d 1369, 1371 (Fed. Cir. 2017)). “orchestrated a scheme to appropriate for themselves inventions from Imperial College . . . in London and the University of South Florida.”13 On December 22, 2011, the Elan Court granted the plaintiff’s motion to stay pending the conclusion of a jury trial in the Avid Lawsuit, finding that the outcome of that trial could be dispositive of the entire action. The Avid Court then held a jury trial on AIA’s standing and, “[b]ased on the jury’s verdict, the district court found AIA

lacked standing to assert the . . . patents and entered judgment in favor of Avid.”14 On March 8, 2012, the Elan Court lifted the stay in the Elan Lawsuit and dismissed the case for lack of standing, finding that collateral estoppel applied as a result of the jury’s determination in the Avid Lawsuit. The Avid Court’s decision on lack of standing was affirmed by the United States Court of Appeals for the Federal Circuit. On March 30, 2015, the Avid Court issued a memorandum opinion finding that the Avid Lawsuit was an “exceptional case” entitling Avid to attorneys’ fees under 35 U.S.C. § 285. The Avid Court’s exceptional-case finding rested upon evidence that AIA knew that it was not the legal owner of the rights to the patents upon which it sued, including evidence of Sexton’s

personal efforts, in cooperation with Dr. Hardy and Dr. Mullan, to defraud the University of South Florida and Imperial College in London of their ownership rights in the invention. On June 5, 2015, the Elan Court found that collateral estoppel also applied to the Avid Court’s determination that the case was exceptional under § 285, and that “an award of attorneys’ fees against AIA was therefore justified in the Elan Lawsuit.”15 On April 14, 2016, the Elan Court entered an order awarding $4,445,492.13 in attorneys’ fees to Eli Lilly and $3,435,130.71 in attorneys’ fees to Elan.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McNutt v. General Motors Acceptance Corp.
298 U.S. 178 (Supreme Court, 1936)
American Fire & Casualty Co. v. Finn
341 U.S. 6 (Supreme Court, 1951)
United Mine Workers of America v. Gibbs
383 U.S. 715 (Supreme Court, 1966)
Bender v. Williamsport Area School District
475 U.S. 534 (Supreme Court, 1986)
Carnegie-Mellon University v. Cohill
484 U.S. 343 (Supreme Court, 1988)
Willy v. Coastal Corp.
503 U.S. 131 (Supreme Court, 1992)
Kokkonen v. Guardian Life Insurance Co. of America
511 U.S. 375 (Supreme Court, 1994)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Aspex Eyewear, Inc. v. Clariti Eyewear, Inc.
605 F.3d 1305 (Federal Circuit, 2010)
Ridge at Red Hawk, L.L.C. v. Schneider
493 F.3d 1174 (Tenth Circuit, 2007)
Wedgetail, Ltd. v. Huddleston Deluxe, Inc.
576 F.3d 1302 (Federal Circuit, 2009)
Bryner v. Lindberg
429 F. App'x 736 (Tenth Circuit, 2011)
Kansas Penn Gaming, LLC v. Collins
656 F.3d 1210 (Tenth Circuit, 2011)
Marctec, LLC v. Johnson & Johnson
664 F.3d 907 (Federal Circuit, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Elan Pharmaceuticals, LLC v. Sexton, Counsel Stack Legal Research, https://law.counselstack.com/opinion/elan-pharmaceuticals-llc-v-sexton-ksd-2019.